NeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology

Reuters

2025/07/30

<a href="https://laohu8.com/S/NEO">NeoGenomics</a> Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology

NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer™ LBx, a new blood-based comprehensive genomic profiling (CGP) test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730287071) on July 30, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555432060"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555432060\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555432060?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-30 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555432060","market":"us","top_or_hot":-1,"title":"NeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer™ LBx, a new blood-based comprehensive genomic profiling (CGP) test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730287071) on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-30 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer™ LBx, a new blood-based comprehensive genomic profiling (CGP) test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730287071) on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL9LvXWC:1","article_id":"2555432060","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555432060","pubTimestamp":1753873516,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer LBx, a new blood-based comprehensive genomic profiling  test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","NEO":"NeoGenomics","BK4196":"保健护理服务","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV"},"translate_title":"NeoGenomics Inc.推出PanTracer LBx：一种用于肿瘤学全面基因组图谱的新型液体活检测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":0.9},"content_text":"NeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology\n    \n\n        NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer™ LBx, a new blood-based comprehensive genomic profiling (CGP) test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730287071) on July 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}